Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive
- PMID: 7249898
- DOI: 10.1007/BF01367675
Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive
Abstract
Forty patients with chronic liver disease and portal hypertension but without clinical signs of portasystemic encephalopathy (15 patients with nonalcoholic cirrhosis, 15 patients with alcoholic cirrhosis, and 10 patients with minimal EEG changes) and a control group of 12 patients with chronic alcohol pancreatitis were studied using an extensive psychometric program, which, in the same form, is used for expert reports on driving capacity. Of the cirrhotic patients, 60% were considered unfit to drive; in 25% driving capacity was questionable, 15% (only nonalcoholic cirrhotics) were considered fit to drive. In contrast 75% of the patients with alcoholic pancreatitis were considered fit to drive. Major defects were found only in three heavy alcoholics. Patients with alcoholic cirrhosis scored lower than patients with nonalcoholic cirrhosis. This was due to differences in liver function rather than to the effect of alcohol consumption. Patients with minimal EEG changes were practically all considered unfit to drive.
Similar articles
-
Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability.Metab Brain Dis. 1995 Sep;10(3):239-48. doi: 10.1007/BF02081029. Metab Brain Dis. 1995. PMID: 8830284
-
Neuropsychological aspects of portal-systemic encephalopathy.Metab Brain Dis. 1998 Dec;13(4):361-77. doi: 10.1023/a:1020645110880. Metab Brain Dis. 1998. PMID: 10206827
-
Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance.J Hepatol. 1994 Dec;21(6):1023-8. doi: 10.1016/s0168-8278(05)80612-9. J Hepatol. 1994. PMID: 7699223
-
The Clinical Relevance of Minimal Hepatic Encephalopathy--A Critical Look.Dig Dis. 2015;33(4):555-61. doi: 10.1159/000375348. Epub 2015 Jul 6. Dig Dis. 2015. PMID: 26159273 Review.
-
Neurologic Manifestations of Chronic Liver Disease and Liver Cirrhosis.Curr Probl Diagn Radiol. 2015 Sep-Oct;44(5):449-61. doi: 10.1067/j.cpradiol.2015.03.004. Epub 2015 Mar 20. Curr Probl Diagn Radiol. 2015. PMID: 25908229 Review.
Cited by
-
Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.Cochrane Database Syst Rev. 2019 Jun 17;6(6):CD012334. doi: 10.1002/14651858.CD012334.pub2. Cochrane Database Syst Rev. 2019. PMID: 31204790 Free PMC article.
-
Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability.Metab Brain Dis. 1995 Sep;10(3):239-48. doi: 10.1007/BF02081029. Metab Brain Dis. 1995. PMID: 8830284
-
The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies.Ann Gastroenterol. 2018 Mar-Apr;31(2):151-164. doi: 10.20524/aog.2018.0232. Epub 2018 Feb 1. Ann Gastroenterol. 2018. PMID: 29507462 Free PMC article. Review.
-
Visual attention orienting in liver cirrhosis without overt hepatic encephalopathy.Metab Brain Dis. 1995 Dec;10(4):335-45. doi: 10.1007/BF02109363. Metab Brain Dis. 1995. PMID: 8847996 Clinical Trial.
-
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.Gastroenterology. 2011 Feb;140(2):478-487.e1. doi: 10.1053/j.gastro.2010.08.061. Epub 2010 Sep 21. Gastroenterology. 2011. PMID: 20849805 Free PMC article. Clinical Trial.
References
MeSH terms
LinkOut - more resources
Medical